All Publications

• Changes in glucose-lowering drug use before and after cancer diagnosis in patients with diabetesAbstract

  AIM: This study explores the changes in glucose-lowering drug (GLD) use before and after cancer diagnosis among patients with diabetes. METHODS: New GLD users (1998-2011) living in the Dutch ECR-PHARMO catchment area were selected from the PHARMO Dtabase Network (n=52,228). Those with a primary cancer diagnosis were considered cases (n=3281) and matched with eligible controls (n=12,891) without cancer during follow-up

  Zander s MMJ, Haak HR, van Herk-Sukel MPP, Herings RMC, van dePoll-Franse LV, Johnson JA. Diabetes Metab. 2018 Oct 21; 44 22 - 29.

• Association between use of antidepressants or benzodiazepines and the risk of subsequent fracture among those aged 65+ in the NetherlandsAbstract

  This is the first study to examine the association between antidepressant and benzodiazepine use following a MOF and risk of subsequent fracture in those 65+. Using national data, drug use following MOF showed that the 1-year fully adjusted risk ofsubsequent MOF in those on antidepressants was more than doubled

  van deVen LI, Klop C, Overbeek JA, deVries F, Burden AM, Janssen PK. Osteoporos Int. 2018 Aug 15; 29 2477-2485.

• Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetesAbstract

  AIMS: To compare real-world antidiabetic treatment outcomes over 12 months in obese people with type 2 diabetes mellitus (T2DM) who previously received oral antidiabetic therapy and then initiated a first injectable therapy with liraglutide or basainsulin. PATIENTS AND METHODS: This was a retrospective, propensity score-matched, longitudinal cohort study using real-world data (January 2010 to December 2015) from the Dutch PHARMO Database Network

  Overbeek JA, Heintjes EM, Huisman EL, Tikkanen CK, van Diermen AW, Penning-van Beest FJA, Herings RMC. Diabetes Obes Metab. 2018 May 3; 20 2093-2102.

• Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort StudyAbstract

  BACKGROUND: Despite the concerns about a potential increased risk of skin cancer and lymphoma with the use of topical tacrolimus and pimecrolimus, no population-based studies have given an overview of the use of these drugs in Europe. OBJECTIVE: Toassess the use of topical tacrolimus and pimecrolimus in children and adults in Europe

  Kuiper JG, van Herk-Sukel MPP, Castellsague J, Pottegard A, Berglind IA, Dedman D, Gutierrez L, Calingaert B, Hallas J, Sundstrom A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S. Drugs Real World Outcomes. 2018 May 7; 5 109-116.

• Risk of dipeptidyl-peptidase-4 (DPP-4) inhibitors on site-specific cancer: a systematic review and meta-analysisAbstract

  BACKGROUND: The long-term impact of DPP-4 inhibition is unknown and there are concerns about the influence of DPP-4 inhibition on carcinogenesis of the pancreas and thyroid. As DPP-4 is a rather unselective enzyme present in many tissues, we focuseon all specific cancer types. METHODS: PubMed and EMBASE were searched between Jan 2005 and Apr 2017 to identify studies comparing DPP-4 inhibitors with either placebo or active drugs on cancer risk

  Overbeek JA, Bakker M, van der Heijden Aawa, van Herk-Sukel MPP, Herings RMC, Nijpels G. Diabetes Metab Res Rev. 2018 Mar 23; 34 e3004.

• A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation – JOELLE study)Abstract

  Background: There is a concern that topical tacrolimus and pimecrolimus, indicated for second-line treatment of atopic dermatitis, may increase the risk of lymphoma and skin cancer, particularly in children. Objective: The aim of this study was toompare incidence rates (IRs) of lymphoma and skin cancer between new users of topical tacrolimus or pimecrolimus and users of moderate- to high-potency topical corticosteroids (TCSs) and untreated subjects

  Castellsague J, Kuiper JG, Pottegard A, Anveden Berglind I, Dedman D, Gutierrez L, Calingaert B, van Herk-Sukel MP, Hallas J, Sundstrom A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S. Clin Epidemiol. 2018 10 299-310.

• How Representative are the Patients Included in the CV outcome Trials with SGLT2 Inhibitors of a General Type 2 Diabetes Population? A Large European Observational studyAbstract

  Birkeland K, Bode gard J, Norhammar A, Kuiper J, Georgiado E, Beekman-Hendriks W, Thuresson M, Pignot M, Herings R, Kooy A. Diabetes Obes Metab. 2018 21 968-974.

• Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS projectAbstract

  BACKGROUND: Use of selective COX-2 non-steroidal anti-inflammatory drugs (NSAIDs) (coxibs) has been associated with an increased risk of acute myocardial infarction (AMI). However, the risk of AMI has only been studied for very few NSAIDs that arerequently used. OBJECTIVES: To estimate the risk of AMI for individual NSAIDs

  Masclee GMC, Straatman H, Arfe A, Castellsague J, Garbe E, Herings R, Kollhorst B, Lucchi S, Perez-Gutthann S, Romio S, Schade R, Schink T, Schuemie MJ, Scotti L, Varas-Lorenzo C, Valkhoff VE, Villa M, Sturkenboom Mcjm. PLoS One. 2018 13 e0204746.

• Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort studyAbstract

  Objectives: Describe and compare the risk of cardiovascular and non-cardiovascular mortality in patients whose antidiabetic therapy is modified to include pioglitazone compared with an alternative antidiabetic medication at the same stage of diseasprogression. Research design and methods: This exploratory linked database cohort analysis used pooled health and mortality data from three European countries: Finland, Sweden and the UK

  Strongman H, Christopher S, Majak M, Williams R, Bahmanyar S, Linder M, Heintjes EM, Bennett D, Korhonen P, Hoti F. BMJ Open Diabetes Res Care. 2018 6 e000481.

• Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonistsAbstract

  OBJECTIVE: Acid suppression with histamine-2 receptor antagonists (H2RAs) or proton pump inhibitors (PPIs) is recommended for children with persistent gastroesophageal reflux disease symptoms. In this retrospective, observational postauthorizationtudy, we aimed to assess and compare safety outcomes in pediatric first-time users of esomeprazole, other PPIs or H2RAs

  Houben E, Johansson S, Nagy P, Penning-van Beest FJA, Kuipers EJ, Herings RMC. Curr Med Res Opin. 2017 Nov 24; 34 577-583.